Clinical trial BGB-3111-306
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | BeiGene |
| EudraCT Identifier | 2019-000413-36 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04002297 |
| Inclusion criteria | MCL; 70 years or 65 years with co-morbidities that contraindicate autograft; ECOG 2 |
| Last update |